Glucokinase

Glucokinase製品

• All (16)
• Glucokinase阻害剤 (9)
• Glucokinase活性剤(4)
• Glucokinaseモジュレータ(1)
• 新製品

製品コード	製品名称	製品説明	文献中Selleckの製品使用例	お客様のフィードバック
S7289	PFK15	PFK15 (PFK-015) is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor with IC50 of 207 nM.	Nature, 2025, 10.1038/s41586-025-09328-w Adv Healthc Mater, 2025, e2501417. Cell Commun Signal, 2025, 23(1):104
S7443	AP-III-a4 (ENOblock)	AP-III-a4 (ENOblock) is the first nonsubstrate analogue inhibitor of enolase with IC50 of 0.576 μM.	Cell Div, 2025, 20(1):23 J Exp Clin Cancer Res, 2023, 42(1):1 bioRxiv, 2023, 10.1101/2023.08.01.551011
S7639	3PO	3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) is a small-molecule inhibitor of PFKFB3 with an IC50 of 22.9 μM for recombinant human PFKFB3 protein and does not inhibit PFK-1 activity. It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.	Atherosclerosis, 2025, 405:119223 J Transl Med, 2024, 22(1):954 bioRxiv, 2023, 10.1101/2023.08.01.551011
S8807	PFK158	PFK158 is a potent and selective inhibitor of PFKFB3. It has improved PK properties and causes ~80% growth inhibition in several mouse models of human-derived tumors.	bioRxiv, 2025, 2025.05.25.655979 Life Med, 2023, 2(1):lnad006 Nat Metab, 2022, 4(10):1287-1305
S2155	LY2608204	LY2608204 activates glucokinase (GK) with EC50 of 42 nM. Phase 2.	Sci Rep, 2017, 7:44681 Nat Commun, 2016, 7:11463
S0400	KAN0438757	KAN0438757 is a potent and selective inhibitor of the metabolic kinase PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) with IC50 of 0.19 μM and 3.6 μM for PFKFB3 and PFKFB4, respectively.	Mol Cell Proteomics, 2023, 22(11):100649 Mol Cell Proteomics, 2023, 10.1016/j.mcpro.2023.100649 Research Square, 2023, Version 1
S1830	Oxfendazole	Oxfendazole (RS-8858,Fenbendazole sulfoxide) is a broad spectrum benzimidazole anthelmintic.	Mol Med Rep, 2019, 19(4):2921-2926
S6921	Dorzagliatin	Dorzagliatin (HMS-5552, RO-5305552, Sinogliatin) is a dual-acting glucokinase (GK) activator that improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes.	Pharmaceuticals (Basel), 2025, 18(6)927 bioRxiv, 2025, 2025.04.03.647023 bioRxiv, 2025, 2023.08.11.552890
S3470	ML198	ML198 is a novel activator of glucocerebrosidase (GCase) with an IC50 of 0.4 μM and does not inhibit the enzyme's action, but can facilitate its translocation to the lysosome.
S6496	Genz-123346 free base	Genz-123346 is an inhibitor of GL1 synthase that blocks the conversion of ceramide to GL1, the first step in the biosynthesis of gangliosides and other glycosphingolipids.
E1353	AZD1656	AZD1656 is a potent, selective and orally active activator of glucokinase. AZD1656 has the potential for type 2 diabetes research.	Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
E1703	SF2312	SF2312 is a highly potent inhibitor of Enolase with IC50s of 37.9 nM and 42.5 nM for human recombinant ENO1 and ENO2, respectively, and also is a natural phosphonate antibiotic. SF2312 displays activity against bacteria under anaerobic conditions.
S3527	AM2394	AM-2394 is a structurally distinct glucokinase activator (GKA), activates glucokinase (GK) with an EC50 of 60 nM.
S9112	Kaempferitrin	Kaempferitrin (Lespenefril, Lespedin, Lespenephryl, Kaempferol 3,7-dirhamnoside), isolated from the leaves of Hedyotis verticillata and from Onychium japonicum, has antimicrobial, antioxidant, and anti-inflammatory activities.
E1028	POMHEX	POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer.
E1252	MitoPQ	MitoPQ (MitoParaquat), a mitochondria-targeted redox cycler, enables the selective generation of superoxide within mitochondria and is a useful tool to investigate the many roles of mitochondrial superoxide in pathology and redox signaling in cells and in vivo.
S7289	PFK15	PFK15 (PFK-015) is a potent and selective 6-phosphofructo-2-kinase (PFKFB3) inhibitor with IC50 of 207 nM.	Nature, 2025, 10.1038/s41586-025-09328-w Adv Healthc Mater, 2025, e2501417. Cell Commun Signal, 2025, 23(1):104
S7443	AP-III-a4 (ENOblock)	AP-III-a4 (ENOblock) is the first nonsubstrate analogue inhibitor of enolase with IC50 of 0.576 μM.	Cell Div, 2025, 20(1):23 J Exp Clin Cancer Res, 2023, 42(1):1 bioRxiv, 2023, 10.1101/2023.08.01.551011
S7639	3PO	3PO (3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one) is a small-molecule inhibitor of PFKFB3 with an IC50 of 22.9 μM for recombinant human PFKFB3 protein and does not inhibit PFK-1 activity. It suppresses glucose uptake, and decreases the intracellular concentration of Fru-2,6-BP, lactate, ATP, NAD+, and NADH.	Atherosclerosis, 2025, 405:119223 J Transl Med, 2024, 22(1):954 bioRxiv, 2023, 10.1101/2023.08.01.551011
S8807	PFK158	PFK158 is a potent and selective inhibitor of PFKFB3. It has improved PK properties and causes ~80% growth inhibition in several mouse models of human-derived tumors.	bioRxiv, 2025, 2025.05.25.655979 Life Med, 2023, 2(1):lnad006 Nat Metab, 2022, 4(10):1287-1305
S0400	KAN0438757	KAN0438757 is a potent and selective inhibitor of the metabolic kinase PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) with IC50 of 0.19 μM and 3.6 μM for PFKFB3 and PFKFB4, respectively.	Mol Cell Proteomics, 2023, 22(11):100649 Mol Cell Proteomics, 2023, 10.1016/j.mcpro.2023.100649 Research Square, 2023, Version 1
S1830	Oxfendazole	Oxfendazole (RS-8858,Fenbendazole sulfoxide) is a broad spectrum benzimidazole anthelmintic.	Mol Med Rep, 2019, 19(4):2921-2926
S6496	Genz-123346 free base	Genz-123346 is an inhibitor of GL1 synthase that blocks the conversion of ceramide to GL1, the first step in the biosynthesis of gangliosides and other glycosphingolipids.
E1703	SF2312	SF2312 is a highly potent inhibitor of Enolase with IC50s of 37.9 nM and 42.5 nM for human recombinant ENO1 and ENO2, respectively, and also is a natural phosphonate antibiotic. SF2312 displays activity against bacteria under anaerobic conditions.
E1028	POMHEX	POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer.
S6921	Dorzagliatin	Dorzagliatin (HMS-5552, RO-5305552, Sinogliatin) is a dual-acting glucokinase (GK) activator that improves glycaemic control and pancreatic β-cell function in patients with type 2 diabetes.	Pharmaceuticals (Basel), 2025, 18(6)927 bioRxiv, 2025, 2025.04.03.647023 bioRxiv, 2025, 2023.08.11.552890
S3470	ML198	ML198 is a novel activator of glucocerebrosidase (GCase) with an IC50 of 0.4 μM and does not inhibit the enzyme's action, but can facilitate its translocation to the lysosome.
E1353	AZD1656	AZD1656 is a potent, selective and orally active activator of glucokinase. AZD1656 has the potential for type 2 diabetes research.	Liver Res-Prc, 2023, Volume 7, Issue 2 Pages 124-135
S3527	AM2394	AM-2394 is a structurally distinct glucokinase activator (GKA), activates glucokinase (GK) with an EC50 of 60 nM.
S2155	LY2608204	LY2608204 activates glucokinase (GK) with EC50 of 42 nM. Phase 2.	Sci Rep, 2017, 7:44681 Nat Commun, 2016, 7:11463